Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Genesis Unveils Emerging Technology, HOCl Atomizing, for 'Air Quality Awareness Week'


HOCl atomizing is the safest, most effective, and natural method for controlling airborne contaminants.

FREDERICK, Md., May 8, 2024 /PRNewswire/ -- Frederick, MD-based Genesis + HOCL introduces two HOCl atomizing machines for Air Quality Awareness Week. Genesis is the sole U.S. distributor of this technology, previously only available in Japan and South Korea, bringing the Genesis 2.6 and UX4 to the U.S. market for business and residential applications. HOCl atomizing is the safest, most effective, and natural method for controlling airborne contaminants, including viruses, bacteria, mold, and allergens. Genesis + HOCL is distinctive as the only air quality control technology that simultaneously targets harmful pathogens both in the air and on surfaces.

Genesis + HOCL, headquartered in Frederick, MD, is a pioneering company at the forefront of HOCl atomizing technology. Established in 2020, Genesis + HOCL is revolutionizing disinfection with its comprehensive approach. Harnessing the power of Hypochlorous (HOCl), a naturally occurring substance, Genesis + HOCL provides simultaneous air and surface disinfection that is safe, eco-friendly, and highly effective.

With a dedication to innovation and sustainability, the science behind Genesis + HOCL's products has been rigorously evaluated and confirmed by regulatory agencies, healthcare institutions, professional organizations, independent laboratories, and academic institutions in more than 50 countries worldwide.

For more information about Genesis + HOCL and its transformative solutions for air quality and pathogen defense, visit GenesisHOCL.com or contact 301-367-2177.

Media Contact

Daryl Bernard, Owner, Genesis + HOCL, 301-367-2177, [email protected], https://genesishocl.com/

SOURCE Genesis + HOCL


These press releases may also interest you

at 22:00
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...



News published on and distributed by: